Update: 05 November 2020
The first thalassaemia patient has been dosed in the FORTE clinical trial – a Phase 2b clinical trial that will evaluate the safety and tolerability of IMR-687 in 120 adult TDT and NTDT patients.
IMR-687 is an oral, once a day therapy that aims to block PDE9 (a signalling molecule) in order to reactivate fetal haemoglobin thus improving symptoms and lowering the disease burden.
An interim analysis of results is expected when 30 patients reach 24 weeks of treatment. Additional results will be analysed when 30 patients have reached 36 weeks of treatment.
Update: 25 August 2020
Imara recently initiated a Phase 2b clinical trial of IMR-687 in adult patients with beta-thalassaemia and expects to dose the first patient in the near-term.
IMR-687 aims to block PDE9 (a signalling molecule) in order to reactivate fetal haemoglobin thus improving symptoms and lowering the disease burden.
U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation, Fast Track designation and Rare Pediatric Disease designation for IMR-687, for the treatment of beta-thalassaemia.